Genmab chief on sclerosis drug launch: Novartis prioritizes us

While Genmab's partner Novartis can start launching sclerosis drug Kesimpta in Europe after receiving EU authorization, the process is well underway in the US – and it's going well, according to CEO Jan van de Winkel.

Genmab CEO Jan van de Winkel | Photo: Stine Bidstrup/ERH

On Tuesday, the EU Commission approved the drug Kesimpta, which was developed by Genmab, as a treatment for sclerosis.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs